The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL

B-cell lymphoma 2 (BCL-2) has recently emerged as a therapeutic target for early T-cell progenitor acute lymphoblastic leukemia (ETP-ALL), a high-risk subtype of human T-cell ALL. The major clinical challenge with targeted therapeutics, such as the BCL-2 inhibitor ABT-199, is the development of acqu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood Adv
Hauptverfasser: Di Grande, Alessandra, Peirs, Sofie, Donovan, Paul D., Van Trimpont, Maaike, Morscio, Julie, Lintermans, Beatrice, Reunes, Lindy, Vandamme, Niels, Goossens, Steven, Nguyen, Hien Anh, Lavie, Arnon, Lock, Richard B., Prehn, Jochen H. M., Van Vlierberghe, Pieter, Ní Chonghaile, Triona
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2021
Schlagworte:
Lymphoid Neoplasia
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8045507/
https://ncbi.nlm.nih.gov/pubmed/33830207
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2021004177
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge